Feed / SLXN

Silexion Therapeutics Corp

SLXN

Healthcare · 0.36 +2.7% today

Isolated · not yet confirmedMarket checked 11 Sept, 12:05 GMT-4

Market read

Silexion Therapeutics Corp's current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 15 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.

Company+2.7% todayVolume comparison unavailable
Market group0 of 15 activeCloud and AI Solutions · unavailable
Disclosed network0 of 5 confirmingNo filing-linked name is confirming now
What would change this read
  • SLXN's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if SLXN's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Biotechnology

No new filing conclusion is available. 0 of 15 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • SLXN's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods0
Price observations319
Usable filing statements31
Verified relationships5
Evidence supporting the case

No qualifying supportive evidence was identified.

Evidence challenging the case

No qualifying adverse evidence was identified; that is not proof there is no downside.

Questions before a position

No credible peer-relative valuation comparison is available yet.

Longer-term price context

Price as of Sep 10, 2026

0.42
6m-75.6%12m-94.2%24m

What management says matters

Persistent and emerging business drivers

Product pipeline and R&Dnegative · 2 filings
The decrease was mainly due to a decrease in our research and development expenses, general and administrative expenses, and financial expenses including significant non-cash items related to share-based compensation, transaction costs and costs related to be…
10-Q · Nov 12, 2025

Valuation discipline

Peer-relative valuation withheld

Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.

Scenario scaffold

Fewer than 4 annual revenue periods; too little history to scaffold scenarios.

Price action

How the market is pricing the story

0.36+2.7% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 12:05 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for SLXN. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for SLXN. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind SLXN

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

AZNAstraZeneca PLCpartnerMar 17, 2026

For example, there are an increasing number of companies commercializing treatments and/or developing programs specifically targeting KRAS mutations, including KRAS G12D and KRAS G12V, in a variety of manners and for a variety of indications, including cancer…

GILDGilead Sciences, Inc.partnerMar 17, 2026

For example, there are an increasing number of companies commercializing treatments and/or developing programs specifically targeting KRAS mutations, including KRAS G12D and KRAS G12V, in a variety of manners and for a variety of indications, including cancer…

LGHLFiling-linked namepartnerMar 17, 2026

Under the ELOC Agreement, we had the right to request to sell to White Lion, and White Lion was required to purchase, via private placement transactions, up to $15.0 million of our ordinary shares from time to time after the Closing under the ELOC, up until D…

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

SLXN is currently a Follower in the organic co-movement group Cloud and AI Solutions. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for SLXN; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.